Identifying Immune Suppressor Candidates in Histiocytic Sarcoma
Author Information
Author(s): Lenz Jennifer A., Peng Brandon, Assenmacher Charles‑Antoine, King Austin, Zhang Paul J., Maki Robert G., Blanco M. Andres, Radaelli Enrico, Atherton Matthew J.
Primary Institution: University of Pennsylvania
Hypothesis
Canine histiocytic sarcoma can serve as a translational model to identify immune suppressor candidates relevant to human histiocytic sarcoma.
Conclusion
The study identifies PD-1, osteopontin, and TXNIP as potential therapeutic targets in histiocytic sarcoma.
Supporting Evidence
- Canine histiocytic sarcoma shares clinical and genetic similarities with human histiocytic sarcoma.
- Increased tumor infiltrating lymphocyte density is associated with better outcomes in canine histiocytic sarcoma.
- PD-1 and osteopontin were identified as differentially expressed genes in canine histiocytic sarcoma.
- TXNIP was found to be the most significant negative differentially expressed gene.
Takeaway
Researchers studied dog tumors to find new ways to help treat a rare cancer that affects both dogs and humans.
Methodology
Transcriptional profiling was performed on tumor samples from dogs with different survival outcomes and compared to normal tissues.
Potential Biases
Potential bias due to the selection of specific tumor types and the reliance on previously published data.
Limitations
The study is limited by the small sample size and the use of grossly normal tissues as controls.
Participant Demographics
Canine patients with histiocytic sarcoma.
Statistical Information
P-Value
1.60E-08
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website